Odapipam
≈ 2 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Odapipam ( ; developmental code names NNC 01-0756, NNC-756, NO-756) is a selective D 1 receptor antagonist of the benzazepine group which was investigated as a potential antipsychotic but was never marketed. It has more than 5,000-fold selectivity for the dopamine D 1 receptor (K i = 0.17 nM) over the dopamine D 2 receptor (K i = 942 nM). Its affinities for other dopamine receptors, such as the dopamine D 5 receptor, were not reported. In addition to the dopamine D 1 receptor, odapipam showed relatively high affinity for the serotonin 5-HT 2 receptor (K i = 4.5 nM; 26-fold lower than for the D 1 receptor). The drug was first described in the scientific literature by 1988.
Odapipam ( ; developmental code names NNC 01-0756, NNC-756, NO-756) is a selective D 1 receptor antagonist of the benzazepine group which was investigated as a potential antipsychotic but was never marketed. It has more than 5,000-fold selectivity for the dopamine D 1 receptor (K i = 0.17 nM) over the dopamine D 2 receptor (K i = 942 nM). Its affinities for other dopamine receptors, such as the dopamine D 5 receptor, were not reported. In addition to the dopamine D 1 receptor, odapipam showed relatively high affinity for the serotonin 5-HT 2 receptor (K i = 4.5 nM; 26-fold lower than for the D 1 receptor). The drug was first described in the scientific literature by 1988.
See also
Substituted 3-benzazepine List of investigational antipsychotics Berupipam (NNC 22-0010) Ecopipam (SCH-39166) NNC 01-0687 (ADX-10061) SCH-23390
References
Text derived from https://en.wikipedia.org/w/index.php?oldid=1372025031 under CC BY-SA 4.0; modifications have been made.